Pacific Growth Initiates Coverage on Aradigm (ARDM) with a Buy
More News related to ARDM
- Aradigm Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
- Aradigm Announces Third Quarter 2009 Financial Results
- Aradigm to Present at the 8th Annual BIO Investor Forum on October 28
- Piper Jaffray Initiates Aradigm Corporation (ARDM) with a Buy
- Pacific Growth Initiates Coverage on Aradigm (ARDM) with a Buy
Pacific Growth initiates coverage on Aradigm (OTC: ARDM) with a Buy.
Aradigm Corporation is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists.
Related Categories
New CoverageStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
